Fluoropharma Medical Inc (FPMI) 0.3800 $FPMI
FluoroPharma Medical to Present Business Updates at the Noble Financial Capital Markets' Eleventh Annual Equity Conference January 21, 2015
Marketwired - Fri Jan 16, 4:08PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that its VP Marketing, Ed Lyons, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Wednesday January 21st at 9:30am Eastern Standard Time.
FluoroPharma Medical Announces Scheduled Completion of Enrollment in a Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Coronary Artery Disease (CAD)
Marketwired - Thu Dec 04, 10:00AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that enrollment for this Phase II trial will be closing on December 15th . To date, FluoroPharma believes it has acquired sufficient patient data allowing for the assessment of the pharmaceutical's safety and quality of FCPHA generated cardiac images in humans.
Journal of Nuclear Cardiology Publication States Preliminary Findings of Phase II Clinical Study Suggest FluoroPharma's CardioPET Has a Promising Role for the Identification of Functionally Significant Coronary Artery Disease
Marketwired - Mon Nov 03, 7:55AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced an online publication in the Journal of Nuclear Cardiology on October 25, 2014 titled "A New F-18 Labeled PET Tracer For Fatty Acid Imaging."
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 19, 2014, in Gothenburg, Sweden
Marketwired - Mon Oct 20, 7:32AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that new Phase II data related to CardioPET (18-F FCPHA) for the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients was presented by Dr. Fabian Demeure, an author of the abstract, at the session: Cardiovascular System: Cardiac PET Imaging on October 19th at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden.
FluoroPharma Medical Announces Acceptance of Abstract from Phase II Clinical Trial of CardioPET (18F FCPHA) for Oral Presentation at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden
Marketwire - Mon Oct 06, 6:30AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased to announce that its abstract has been accepted for oral presentation at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden.
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the 19th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC), September 20th in Boston, MA
Marketwire - Mon Sep 22, 10:25AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that new Phase II data related to CardioPET (18-F FCPHA) for the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients was presented at the 19th Annual Scientific Session of ASNC, held this weekend, by the lead author of the abstract, Dr. Manuel Cerqueira.
FluoroPharma Medical Announces Acceptance of Abstract From Phase II Clinical Trial of CardioPET (18F FCPHA) for Oral Presentation at the 19th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC), September 18-21, 2014, in Boston
Marketwire - Tue Sep 02, 7:14AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased to announce that its Abstract has been accepted for oral presentation at the 19th Annual Scientific Session of ASNC. Data from FluoroPharma's ongoing Phase II clinical trial for CardioPET (18F FCPHA) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients, will be presented on September 20, 2014 at Session 308: 10:30AM-12:00PM, by Dr. Manuel Cerqueira, Chairman, Department of Nuclear Medicine at the Cleveland Clinic and co-author of the Abstract.
Eagle Pharmaceuticals (EGRX) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:21AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
ADXS: 7.18 (+0.06), CTSO: 8.20 (+0.18), EGRX: 20.98 (+1.45)
FluoroPharma Medical to Present Business Updates at the Noble Financial Capital Markets' Eleventh Annual Equity Conference January 21, 2015
Marketwired - Fri Jan 16, 4:08PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that its VP Marketing, Ed Lyons, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Wednesday January 21st at 9:30am Eastern Standard Time.
FluoroPharma Medical Announces Scheduled Completion of Enrollment in a Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Coronary Artery Disease (CAD)
Marketwired - Thu Dec 04, 10:00AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that enrollment for this Phase II trial will be closing on December 15th . To date, FluoroPharma believes it has acquired sufficient patient data allowing for the assessment of the pharmaceutical's safety and quality of FCPHA generated cardiac images in humans.
Journal of Nuclear Cardiology Publication States Preliminary Findings of Phase II Clinical Study Suggest FluoroPharma's CardioPET Has a Promising Role for the Identification of Functionally Significant Coronary Artery Disease
Marketwired - Mon Nov 03, 7:55AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced an online publication in the Journal of Nuclear Cardiology on October 25, 2014 titled "A New F-18 Labeled PET Tracer For Fatty Acid Imaging."
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 19, 2014, in Gothenburg, Sweden
Marketwired - Mon Oct 20, 7:32AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that new Phase II data related to CardioPET (18-F FCPHA) for the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients was presented by Dr. Fabian Demeure, an author of the abstract, at the session: Cardiovascular System: Cardiac PET Imaging on October 19th at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden.
FluoroPharma Medical Announces Acceptance of Abstract from Phase II Clinical Trial of CardioPET (18F FCPHA) for Oral Presentation at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden
Marketwire - Mon Oct 06, 6:30AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased to announce that its abstract has been accepted for oral presentation at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden.
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the 19th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC), September 20th in Boston, MA
Marketwire - Mon Sep 22, 10:25AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that new Phase II data related to CardioPET (18-F FCPHA) for the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients was presented at the 19th Annual Scientific Session of ASNC, held this weekend, by the lead author of the abstract, Dr. Manuel Cerqueira.
FluoroPharma Medical Announces Acceptance of Abstract From Phase II Clinical Trial of CardioPET (18F FCPHA) for Oral Presentation at the 19th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC), September 18-21, 2014, in Boston
Marketwire - Tue Sep 02, 7:14AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased to announce that its Abstract has been accepted for oral presentation at the 19th Annual Scientific Session of ASNC. Data from FluoroPharma's ongoing Phase II clinical trial for CardioPET (18F FCPHA) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients, will be presented on September 20, 2014 at Session 308: 10:30AM-12:00PM, by Dr. Manuel Cerqueira, Chairman, Department of Nuclear Medicine at the Cleveland Clinic and co-author of the Abstract.
Eagle Pharmaceuticals (EGRX) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:21AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
ADXS: 7.18 (+0.06), CTSO: 8.20 (+0.18), EGRX: 20.98 (+1.45)
